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The majority of AIDS-associated primary effusion lymphomas (PEL) are latently infected with both Kaposi’s
sarcoma-associated herpesvirus (KSHV) and Epstein-Barr virus (EBV). PELs harboring two viruses have
higher oncogenic potential, suggesting functional interactions between EBV and KSHV. The KSHV replication
and transcription activator (K-RTA) is necessary and sufficient for induction of KSHV lytic replication. EBV
latent membrane protein 1 (LMP-1) is essential for EBV transformation and establishment of latency in vitro.
We show EBV inhibits chemically induced KSHV lytic replication, in part because of a regulatory loop in which
K-RTA induces EBV LMP-1 and LMP-1 in turn inhibits K-RTA expression and furthermore the lytic gene
expression of KSHV. Suppression of LMP-1 expression in dually infected PEL cells enhances the expression
of K-RTA and lytic replication of KSHV upon chemical induction. Because LMP-1 is known to inhibit EBV lytic
replication, KSHV-mediated induction of LMP-1 would potentiate EBV latency. Moreover, KSHV infection of
EBV latency cells induces LMP-1, and K-RTA is involved in the induction. Both LMP-1 and K-RTA are
expressed during primary infection by EBV of KSHV latency cells. Our findings provide evidence that an
interaction between EBV and KSHV at molecular levels promotes the maintenance and possibly establishment
of viral latency, which may contribute to pathogenesis of PELs.
EBV latent membrane protein 1 (LMP-1) is required for
EBV transformation of primary B cells and establishment of
EBV latency in vitro and is believed to play similar roles in
EBV-associated tumor cells in vivo (45, 47). LMP-1 is an integral membrane protein and acts as a constitutively active
receptor-like molecule that does not need a ligand (30, 36, 46,
54). LMP-1 activates a variety of cellular genes that enhance
cell survival and adhesive, invasive, angiogenic, and antiviral
potential (31, 41, 59, 81–83, 87, 90, 94, 95).
Interestingly, the majority of PELs are harboring both EBV
and KSHV (13, 14, 42, 68). In order to understand their contributions to the pathogenesis of PEL, it is important to address how EBV and KSHV interact with each other and affect
biological properties of the cell and the viruses. PELs harboring two viruses have higher oncogenic potential (76), suggesting potential interactions between EBV and KSHV. This report describes a molecular interaction between EBV and
KSHV, i.e., KSHV K-RTA potentiates EBV latency via induction of EBV LMP-1 and uses LMP-1 to curb KSHV lytic
replication. These data suggest that the coinfection of EBV
and KSHV in the majority of body cavity-based lymphomas
might not be a coincidence: the presence of EBV is one of the
strategies that KSHV uses for the maintenance of its latency.
This report should be applicable to both KSHV and EBV
studies in the majority of AIDS-associated PELs.

Both Epstein-Barr virus (EBV) and Kaposi’s sarcoma-associated herpesvirus (KSHV), also called human herpesvirus 8,
are members of the human gammaherpesviruses and are associated with a variety of human malignancies. EBV is an
important cause of lymphomas in severely immunocompromised persons, especially patients with AIDS and organ-transplant recipients (46, 61, 62, 64, 66). KSHV is believed to be the
etiological agent of Kaposi’s sarcoma(16, 18, 60) and is implicated in the pathogenesis of AIDS-associated primary effusion
lymphoma (PEL), also called body cavity-based lymphoma,
and multicentric Castleman’s disease (23, 60, 86).
Like other herpesviruses, EBV and KSHV go through both
latency and lytic replication cycles. The KSHV replication and
transcription activator (K-RTA) is necessary and sufficient for
the switch from latency to lytic replication in KSHV (23, 86,
88). K-RTA is a sequence-specific DNA-binding protein that
regulates many subsequently expressed viral genes (38, 56, 69,
70, 75, 91, 97). Also, K-RTA can interact with other factors to
modulate its transcription potential (39, 40, 51–53).
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MATERIALS AND METHODS
Cell culture, plasmids, adenoviruses, and antibodies. All cell lines used in this
study and their properties are listed in Table 1. Expression plasmids for K-RTA
(pCMV50) and the recombinant adenoviruses for green fluorescence protein
(GFP) (AdGFP) and K-RTA (AdRTA) were a gift from Byrd Quinlivan (71).
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TABLE 1. Cell lines used in this study and their propertiesa
Cell line

BC-1
HBL-6
JSC-1
BC3
BC3-EBV (cl 10)
BCBL-1
Cro6
Cro6-EBV (cl 2)
IB-4
P3HR1
DG75
293T
293-EBV
BRLF-KO
BZLF1-KO
AGS-BX1g
a

Properties (reference)
⫹

⫹

Growth conditions

EBV , KSHV , PEL line (15)
EBV⫹, KSHV⫹, PEL line (33)
EBV⫹, KSHV⫹, PEL line (12)
EBV⫺, KSHV⫹, PEL line (5)
EBV⫹, KSHV⫹, PEL line (76)
EBV⫺, KSHV⫹, PEL line (65)
EBV⫺, KSHV⫹, PEL line (76)
EBV⫹, KSHV⫹, PEL line (76)
EBV⫹, KSHV⫺, EBV-transformed lymphoblastoid
cell line (48)
EBV⫹, KSHV⫺, Burkitt’s lymphoma line; EBNA-2 is
deleted in viral genome (2)
EBV⫺, KSHV⫺, Burkitt’s lymphoma line (7)
EBV⫺, KSHV⫺, fibroblast
EBV⫹, KSHV⫺, 293 fibroblast-derived wild-type
EBV genome (27)
EBV⫹, KSHV⫺, 293 fibroblast derived; lacking
BRLF1 gene in EBV genome (27)
EBV⫹, KSHV⫺, 293 fibroblast derived; lacking
BZLF1 gene in EBV genome (27)
EBV⫹, KSHV⫺; GFP gene is present in EBV
genome (9)

RPMI
RPMI
RPMI
RPMI
RPMI
RPMI
RPMI
RPMI
RPMI

1640
1640
1640
1640
1640
1640
1640
1640
1640

⫹
⫹
⫹
⫹
⫹
⫹
⫹
⫹
⫹

10%
10%
10%
20%
20%
10%
20%
20%
10%

FBS
FBS
FBS
FBS
FBS ⫹ G418 (2.5 mg/ml)
FBS
FBS
FBS ⫹ G418 (1 mg/ml)
FBS

RPMI 1640 ⫹ 10% FBS
RPMI 1640 ⫹ 10% FBS
DMEM ⫹ 10% FBS
DMEM ⫹ 10% FBS ⫹ hygromycin (0.5 mg/ml)
DMEM ⫹ 10% FBS ⫹ hygromycin (0.5 mg/ml)
DMEM ⫹ 10% FBS ⫹ hygromycin (0.5 mg/ml)
DMEM ⫹ 10% FBS ⫹ G418 (0.5 mg/ml)

All listed lines are human cell lines. Phenotypes, genotype, properties, and culture conditions are as shown.

The K-RTA K152E mutant is a DNA-binding mutant of K-RTA (91). The
recombinant adenovirus for LMP-1 (AdLMP1) was a gift from Stephen
Gottschalk and Cliona Rooney (37). The ␤-galactosidase expression plasmid,
pCMV␤, was purchased from Clontech. LMP-1 and LMP-DM, which is a mutant
LMP-1 failing to initiate signals, have been described previously (94). The
LMP-1 promoter reporter constructs were generated by inserting PCR products
into the pGL3-basic vector (Promega). LMP-mISRE-luc is exactly the same as
LMP-ISRE-luc except for the interferon-stimulated response element (ISRE)
mutation. The LMP-1 ISRE (5⬘-AGGAAATGGAAAGG-3⬘) was mutated at
the underlined nucleotides for mISRE (5⬘-AGGGGGTGGGGGGG-3⬘). The
pHP vector was constructed by ligation of the PacI/blunt-XbaI fragment of
pAdTrack-HP (96) into the AseI/blunt-XbaI sites of pEGFP-N1 (ClonTech).
The sequence 5⬘-TGGAACGCGACCTTGAGAG-3⬘ was used to clone the
small interfering RNA for LMP-1 (siLMP-1) expression plasmid in pHP. The
5⬘-TGGCGCAAGATGACAAGGG-3⬘ sequence was used for making siRNA
for K-RTA. The sequence for p53 has been described previously (96). All
constructs were verified by sequence analysis by the UNL Sequencing Facility.
The K-RTA antibody was from David Lukac (all figures except Fig. 1). Rabbit
polyclonal antibody against K-RTA peptide (amino acids 667 to 691), “ATPAN
EVQESGTLYQLHQWRNYFRD,” was customer made by Alpha Diagnostic
International. This K-RTA antibody was used for Fig. 1. The K8 antibody was

from Jae Jung. Tubulin antibody was purchased from Sigma. EBV E-RTA and
EA-D antibodies were purchased from Argene, LMP-1 antibody (CS1-4) was
from Dako, and STAT-1 monoclonal antibody was from Santa Cruz. Rat monoclonal antibody to KSHV latency-associated nuclear antigen was obtained from
ABI. Secondary goat antirat conjugated with cy5 was from Jackson ImmunoResearch.
Enrichment of transfected cells and making cell lines. Enrichment for CD4positive cells was performed with the use of anti-CD4 antibody conjugated to
magnetic beads according to the manufacturer’s recommendation (Dynal). The
isolated cells were lysed immediately and used for Western blot analysis. However, for chemical treatment, cells were detached from Dynabeads CD4 by
incubation for 45 to 60 min at room temperature with 10 l of DETACHaBEAD
(Dynal). The detached beads were removed by using a magnet separation device.
The released cells were washed two to three times with 500 l RPMI 1640 plus
10% fetal bovine serum (FBS) and resuspended in RPMI 1640 plus 10% FBS at
5 ⫻ 105 cells/ml. Cells were recovered for 2 to 6 h before the addition of chemical
reagents. BC1 (EBV⫹ KSHV⫹) cells were transfected with either pHP (control)
or pHP-siLMP-1 (siLMP-1) along with a CD4 expression plasmid, and the
transfected cells were enriched and cultured in the presence of G418 (1 mg/ml)
and 20% FBS for 1 week to make cell lines. The cells were then treated by
chemicals for induction of lytic replication.

FIG. 1. EBV inhibits KSHV lytic gene expression. (A) EBV inhibits KSHV lytic gene expression in BC3 cells. BC3 cells and their EBV-infected
counterparts, BC3-EBV cells, were treated with sodium butyrate (0.5 and 1 mM) for 12 to 16 h. Lysates were separated by 10% SDS-PAGE,
transferred, and used for Western blot analysis. The membrane was cut in the middle and probed with different antibodies. Identities of proteins
are as shown. (B) EBV inhibits KSHV lytic gene expression in Cro6 cells. Cro6 cells and their EBV-infected counterparts, Cro6-EBV cells, were
treated with sodium butyrate for 12 to 16 h. Lysates were used for Western blot analysis. The same membrane was stripped and reprobed with other
antibodies. One representative from three experiments is shown. Identities of proteins are as shown.
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Preparation of KSHV stocks and in vitro infections. BCBL-1 cells were
treated with 12-O-tetradecanoyl phorbol-13-acetate (TPA) (30 ng/ml) and sodium butyrate (3 mM) to induce the lytic cycle of KSHV replication, and culture
supernatants were harvested 7 days later. Virions were pelleted by centrifugation
at 100,000 ⫻ g for 1 h. Virion pellets were subsequently resuspended in complete
medium (1:100 of the volume of the original supernatants) and were passed
through a 0.45-m filter. For infection, 293-EBV or BZLF1-KO cells at approximately 50% confluence were incubated with concentrated viruses. After incubation at 37°C for 24 h, cells were washed and cell lysates were used for detection
of target proteins.
Preparation of EBV stocks and in vitro infections. EBV lytic replication of
AGS-BX1-g cells was induced by 0.5 mM sodium butyrate and 30 ng/ml of TPA.
Media were replaced with fresh media without TPA and butyrate after 24 h.
Media were collected 4 days later with or without concentration and passed
through a 0.45-m filter. For infection, Cro6 cells were incubated with 0.5 or 1
ml of EBV stock. After incubation at 37°C for 24 h, cells were collected and RNA
was isolated for reverse transcription-PCR (RT-PCR) analysis. Infectivity was
examined by detecting GFP-positive cells under a UV microscope. Similar results were obtained with concentrated or nonconcentrated EBV viruses (data not
shown).
Transient transfection, adenovirus infection, and Reporter assays. Effectene
(QIAGEN) was used for the transfection of 293-EBV, BRLF1-KO, and 293T
cells. Electroporation was used for transfection of BC3 and DG75 cells. The
recombinant adenoviruses were titered in 293 cells. BRLF1-KO cells were infected with adenovirus at a multiplicity of infection of 5 (calculated from PFU),
while a multiplicity of infection of 100 was used for infection of BC3 cells. The
luciferase assays were performed using the assay kit from Promega according to
the manufacturer’s recommendation.
EMSA. Expression and purification of KSHV RTA proteins have been described previously (91). The probes were obtained by first annealing complementary oligonucleotides and then labeling them with [␣-32P]dCTP (Amersham)
using DNA polymerase Klenow fragment (Fermentas). The LMP-1 ISRE probe
was obtained by annealing two oligonucleotides, 5⬘-GATCGCAACAGGAAAT
GGAAAGGC-3⬘ and its complementary strand, with GATC at the 5⬘ end. An
electrophoretic mobility shift assay (EMSA) was performed essentially as described previously (73, 91).
Induction of KSHV lytic replication. BC3 cells were treated with 5 to 10 ng/ml
TPA for 18 to 24 h to induce lytic viral replication. For BC1 cells, 0.5 to 1 mM
sodium butyrate was used for 18 to 24 h for the induction of KSHV lytic
replication. For experiments shown in Fig. 1, BC3, BC3-EBV (clone [cl] 10),
Cro6, and Cro6-EBV (cl 2) cells were treated with sodium butyrate at 0.5 to 1 mM.
Western blot analysis, RNA extraction, RPA, and RT-PCR. Standard Western
blot analysis was performed as described previously (92). Total RNA was isolated
from cells using the RNeasy Total RNA isolation kit (QIAGEN). RNase protection assays (RPA) were performed with total RNA using the RNase Protection Assay Kit II (Ambion) as described previously (93). The glyceraldehyde-3phosphate dehydrogenase (GAPDH) probe was from U.S. Biochemicals, Inc.
The probe for LMP-1 was a gift from Joseph Pagano. Reverse transcription was
performed with the use of the SuperScript reverse transcription system from
Invitrogen, following the manufacturer’s recommended protocol. Reverse-transcribed cDNA (2 l) was then PCR amplified with the appropriate primers. PCR
conditions were as follows: initial denaturation at 95°C for 3 min, followed by 30
to 35 cycles of 95°C for 30 s, 62°C for 1 min, and 72°C for 1 min and a final
extension at 72°C for 10 min. Amplified DNA was then resolved by 8% polyacrylamide gel electrophoresis (PAGE). Primers used for LMP-1 were 5⬘-TGA
TCATCTTTATCTTCAGAAGAGACCTT-3⬘ and 5⬘-CCTGTCCGTGCAAAT
TCCA-3⬘; for K-RTA, 5⬘-CGCAATGCGTTACGTTGTTG-3⬘ and 5⬘-GCCCG
GACTGTTGAATCG-3⬘; and for actin, 5⬘-TTCTACAATGAGCTGCGTGT-3⬘
and 5⬘-GCCAGACAGCACTGTGTTGG-3⬘.
Cell lysates and immunoprecipitation. Cells (108) were collected by centrifugation and were resuspended in 1 ml of extraction buffer (0.5% NP-40, 0.3 M
NaCl, 0.1 mM EDTA, 20 mM HEPES [7.4], 1 mM dithiothreitol, and 10%
glycerol), supplemented with complete protease inhibitors (Roche). The cell
suspension was kept in 4°C for 30 min with gentle agitation. Insoluble material
was pelleted at 14,000 ⫻ g for 15 min at 4°C, and the supernatant was used
directly for immunoprecipitation. A specific antibody was added to the lysates,
followed by addition of 40 l of protein G Sepharose (Pharmacia), and the
sample was incubated overnight at 4°C with continuous mixing. Protein immunocomplexes were isolated by centrifugation, and beads were washed three times
with extraction buffer. Immunoprecipitated proteins were resuspended in sodium
dodecyl sulfate (SDS)-PAGE loading buffer and analyzed by SDS-PAGE, and
Western blot analyses were employed with specific antibodies.

J. VIROL.

RESULTS
EBV inhibits lytic replication of KSHV. Because the majority of the current studies on KSHV and EBV use singly infected cells as a model system, the potential effects of EBV and
KSHV on each other’s biology obviously need attention. We
thus examined the effect of EBV on the KSHV lytic replication
process. BC3 and Cro6 are KSHV⫹ EBV⫺ PEL lines. Isogenic
dually infected cell lines were generated by EBV infection
(76). The expression of the entire panel of EBV latent genes,
including those for EBV nuclear antigen 1 (EBNA-1), -2, -3,
-4, and -6, LMP1, -2A, and -2B, and EBV-encoded small
RNAs, was examined with these isogenic cell lines. All EBVinfected clones of the PEL cells expressed EBNA-1, EBVencoded small RNA 1, and LMP2A. EBNA2 to -6 were not
expressed in any of the converted lines. The expression of
LMP-1 was heterogeneous as determined by Western blot
analyses: Cro6-EBV (cl 2) expressed LMP-1 protein. BC3EBV (cl 10) had no detectable LMP-1 protein (76). We now
have shown that LMP-1 is expressed in both BC3-EBV and
Cro6-EBV lines in an RT-PCR assay (see Fig. S1 in the supplemental material). All these data suggested that EBV
formed type II latency with low levels of LMP-1 expression in
these EBV convertants used in present study, which is in agreement with previous reports about EBV status in dually infected
cells (11, 26, 42, 50).
Most isogenic cell lines are made and cultured for some time
and have not encountered any major loss of EBV, primarily
due to the fact that these EBV-infected PELs are maintained
in G418 selection. Because recombinant EBV containing GFP
was used for the establishment of isogenic lines, expression of
GFP could be used to identify these EBV-positive cells. We
found that these EBV convertants were 100% positive for
KSHV as determined by the expression of KSHV latencyassociated nuclear antigen (also called ORF73) (see Fig. S2A
in the supplemental material) and 65% and 85% GFP positive
for BC3-EBV and Cro6-EBV, respectively (see Fig. S2B in the
supplemental material). Thus, BC3-EBV and Cro6-EBV had
65 and 85% cells, respectively, that were dually infected by
both KSHV and EBV.
KSHV lytic replication can be induced by some chemicals,
such as sodium butyrate. The cells were treated with the same
amounts of sodium butyrate, and KSHV lytic gene expression
was examined by Western blot analyses. As shown in Fig. 1,
expression of the K-RTA and K8 genes was detected after the
treatment, indicating the initiation of lytic replication processes. However, in the presence of EBV, K-RTA and K8 were
expressed at lower levels (Fig. 1). Because both K-RTA and K8
are essential genes required for KSHV lytic replication (6, 43,
88), these results suggested that EBV inhibited sodium butyrate-induced KSHV lytic replication.
KSHV RTA induces expression of EBV LMP-1 protein. The
EBV LMP-1 promoter region has three kinds of cis elements
through which K-RTA could possibly regulate: RBP-J binding
sequence (RBP-J), ISRE, and gamma interferon activation sequence (GAS) (40, 51, 52, 91) (see Fig. 4A). We thus tested if
K-RTA could induce the expression of LMP-1. The recombinant
adenoviruses containing K-RTA (AdRTA) or GFP (AdGFP)
were used to infect a BRLF-1-KO cell line (EBV⫹ KSHV⫺) (27).
The EBV BRLF1 gene product (or E-RTA) has been shown to
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FIG. 2. KSHV K-RTA induces expression of EBV LMP-1. (A) Recombinant adenovirus containing K-RTA induces expression of LMP-1.
Lysates from uninfected or AdRTA- or AdGFP-infected BRLF1-KO cells were used for Western blot analysis. BRLF1-KO contains EBV
BRLF1-null genome. The same membrane was stripped and reprobed with other antibodies. Identities of proteins are as shown. (B) Transfection
of K-RTA induces expression of EBV LMP-1. Lysates from pcDNA3 (vector)-, K-RTA-, or E-RTA-transfected BRLF1-KO cells were used for
Western blot analysis. (C) Induction of LMP-1 by K-RTA is independent of EBNA-2. K-RTA or K-RTA K152E plasmids were transfected into
P3HR1 cells with the CD4 expression plasmid, and transfected cells were selected by CD4 magnetic beads. P3HR1 is an EBV⫹ line with EBNA-2
deletion in the genome. Lysates from enriched cells were used for Western blot analysis. The same membrane was stripped and reprobed with other
antibodies. Identities of proteins are as shown.

induce the expression of LMP-1 (17). The use of the BRLF1-KO
cells would eliminate the potential contribution of EBV BRLF1
to LMP-1 induction. As shown in Fig. 2A, endogenous LMP-1
expression was increased significantly in response to AdRTA infection but not to AdGFP infection.
BRLF1-KO cells are generated in human 293 cells in which
recombinant adenovirus can replicate. In order to eliminate
the possible contribution from adenovirus replication, we ex-

amined the effect of K-RTA in transient-transfection assays.
An expression plasmid of K-RTA or the EBV homologue of
K-RTA, E-RTA (EBV BRLF1 gene product), was transfected
into BRLF1-KO cells. As shown in Fig. 2B, K-RTA could
induce the expression of LMP-1; however, E-RTA could not
induce the expression of LMP-1 to similar levels. The inability
of E-RTA to induce LMP-1 might be due to the differences in
cellular background (17). Because LMP-1 is expressed during

FIG. 3. K-RTA induces expression of LMP-1 RNA. (A) K-RTA induces LMP-1 RNA. LMP-1 and GAPDH probes were labeled with
[␣-32P]UTP and used for RPA. Yeast RNA, RNA from IB4 cells (positive control), or RNAs from BRLF1-KO cells transfected with pcDNA3,
K-RTA, or K-RTA-K152E, respectively, were used for RPA analyses. Specific protections of LMP-1 and GAPDH RNAs are indicated.
(B) Relative LMP-1 RNA levels. Data were obtained by normalizing LMP-1 to GAPDH levels from three independent experiments with the use
of a Gene Genius Bioimaging System. Standard deviations are shown. (C) Expression levels of K-RTAs. Lysates from transfected cells were used
for Western blot analysis. The same membrane was stripped and reprobed with other antibodies. Identities of proteins are as shown.
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FIG. 4. KSHV K-RTA activates EBV LMP-1 promoters. (A) Schematic diagram of EBV LMP-1 promoter reporter constructs. RNA start site
is shown. The drawing is not to scale. (B) K-RTA activates EBV LMP-1 promoter reporter constructs. 293T cells were transfected with various
reporter constructs along with the CMV-␤-gal, K-RTA, or K-RTA-K152E expression plasmid as shown on the top. Luciferase activity was
normalized to ␤-galactosidase activity. The n-fold activation of each promoter construct is shown with standard deviation. One representative of
five independent experiments is shown. (C) LMP-1 promoter reporter is activated during KSHV lytic replication. BC3 is a KSHV⫹ EBV⫺ PEL
cell line. The reporter constructs were transfected into BC3 cells by electroporation. After several hours of recovery, the cells were treated with
(⫹) or without (⫺) sodium butyrate (3 mM) for 24 h. The relative promoter activities are shown. (D) K-RTA protein binds to LMP-1 promoter.
The LMP1 ISRE was labeled with [␣-32P]dCTP. Equal amounts of partially purified K-RTA and K-RTA-K152E proteins and purified bovine
serum albumin were used for EMSA. Specific protein-DNA complex is shown.

the EBV lytic replication cycle (8, 20, 67), it is thus possible
that K-RTA might induce EBV lytic replication that results in
the synthesis of LMP-1. However, this scenario is unlikely
because it is well documented that K-RTA is unable to induce
the lytic replication of EBV, and we confirmed the observation
(74; also data not shown). The results thus suggested that
K-RTA-mediated LMP-1 induction is not related to activation
of EBV lytic replication.
Induction of the LMP-1 protein by K-RTA is independent of
EBNA-2. Because EBNA-2 is the primary activator of EBV
LMP-1 (1, 35, 77, 84), it is possible that K-RTA induces the
expression of EBNA-2, which in turn activates LMP-1. P3HR1
(EBV⫹ KSHV⫺) is a Burkitt’s lymphoma line that harbors an
EBV genome without EBNA-2 (2). K-RTA expression plasmids were transfected into P3HR-1 cells along with a CD4
expression plasmid, and the levels of LMP-1 were determined
after selection of the transfected cells by the use of CD4 antibody-conjugated magnetic beads (see Materials and Methods
for details). As shown in Fig. 2C, K-RTA induced a marked
increase in LMP-1 protein levels in P3HR1 cells. Because of
the deletion of EBNA-2 in the P3HR1 EBV genome, these

results indicated that the induction of LMP-1 by K-RTA is, at
least partially, independent of EBNA-2. The mutant, K-RTAK152E, was unable to induce LMP-1. K-RTA-K152E also
failed to induce the LMP-1 protein in BRLF1-KO cells (data
not shown). Because K-RTA-K152E has a defect in DNA
binding capability, DNA binding activity of K-RTA might be
an important component of the induction of LMP-1 (91). KRTA also induced the expression of LMP-1 in EBV latency
cells with both EBNA2 and BRLF1 in the viral genome, suggesting the induction was not a cell-specific phenomenon.
K-RTA induces EBV LMP-1 at the RNA level. Next, we examined whether K-RTA induces LMP-1 at the RNA level. K-RTA
or its mutant K-RTA-K152E was transfected into BRLF1-KO
cells. Total RNA was isolated from transfected cells 24 h later.
RPA were used for detection of LMP-1 RNA. K-RTA-transfected cells have higher LMP-1 RNA levels than vector- or
K-RTA-K152E-transfected cells (Fig. 3A and B). The expression
levels of K-RTA and its mutant were similar (Fig. 3C). Thus,
K-RTA-mediated induction of LMP1 occurs at the RNA level.
K-RTA activates LMP-1 promoter. There are at least three
potential cis elements that may be used by RTA for transacti-
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FIG. 5. LMP-1 inhibits chemically induced lytic replication of
KSHV. (A) EBV LMP-1 inhibits K-RTA expression upon induction of
TPA. Vector, LMP-1, or LMP-DM plasmid was transfected into BC3
(KSHV⫹ EBV⫺) cells along with CD4 expression plasmid, and transfected cells were selected by CD4 magnetic beads. After several hours’
recovery, the cells were treated with TPA, and lysates from enriched
and treated cells were used for Western blot analysis. Identities of
proteins are as shown. (B) Recombinant adenovirus expressing LMP-1
inhibits TPA-induced lytic gene expression. Lysates from AdLMP-1or AdGFP-infected BC3 cells were used for Western blot analysis.
Identities of proteins are as shown.

vation: RBP-J, ISRE, and GAS (40, 51, 52, 91). K-RTA and
various LMP-1 promoter reporter constructs (Fig. 4A) were
transfected into 293T cells, and the promoter activities were
measured. The expression levels of K-RTA and its mutant
were similar (see Fig. S3A in the supplemental material). As
shown in Fig. 4B, K-RTA was able to activate empty
pGL3basic two- to sixfold under our conditions (columns 1 and
2), which is a background issue. The LMP-ISRE-luc reporter
was strongly activated by K-RTA (columns 3 and 4), but the
point mutations or deletion of ISRE crippled activation by
K-RTA (columns 6 to 9). In agreement with the data shown in
Fig. 2C and 3A, the K-RTA-K152E mutant failed to activate
LMP-1 promoter reporter constructs (Fig. 4, column 5). Because LMP-ISRE-luc contains ISRE, RBP-J, and GAS (Fig.
4A), these data suggest that the LMP-1 ISRE is a necessary cis
element in response to K-RTA in the LMP-1 promoter.
Whether the LMP-1 promoter constructs are responsive to
physiological levels of K-RTA was examined. In BC3 (KSHV⫹
EBV⫺) cells, sodium butyrate induced 10-fold activation of
LMP-ISRE-luc; however, only two- to threefold activations
were observed when pGL3-basic or LMP-mISRE-luc was
used for transfection (Fig. 4C). Moreover, in DG75 (EBV⫺
KSHV⫺) cells, sodium butyrate could not activate the LMPISRE-luc reporter construct (data not shown). These data suggest that a viral gene(s) in the lytic replication cycle may be
responsible for activation of the LMP-1 promoter via LMP-1
ISRE. K-RTA is among the earliest gene products expressed in
lytic replication, and its expression was confirmed by Western
blot analyses (see Fig. S3B in the supplemental material).
Thus, the physiological levels of K-RTA might also activate the
LMP-1 promoter construct.
K-RTA binds to LMP-1 promoter. Finally, because K-RTA
is known to bind to the ISRE (91), it is expected that K-RTA
could bind to the LMP-1 ISRE. We first tested if the LMP-1
ISRE was able bind to endogenous K-RTA in lysates from
PEL cells with lytic replication. However, we did not detect any
specific binding (data not shown). Partially purified K-RTA
protein, which has been used widely to study K-RTA binding
(22, 55, 72, 73, 85), was then used for EMSA with the LMP-1
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FIG. 6. Down-regulation of LMP-1 enhances KSHV lytic replication. (A) siLMP-1 repressed LMP-1 expression. 293T cells were transfected with siLMP-1 and LMP-1 expression plasmid. Cell lysates were
used for Western blot analysis. Identities of proteins are as shown.
(B) siLMP-1 repressed LMP-1 expression in dually infected PEL.
Concentrated cell lysates from control and siLMP-1-expressing BC1
(KSHV⫹ EBV⫹) cells were used for Western blot analysis. Identities
of proteins are as shown. n.s., nonspecifc. (C) siLMP-1 enhanced
expression of KSHV lytic proteins. siLMP-1 expression and its control
in BC-1 cells were treated with sodium butyrate for 18 h. Lysates were
used for Western blot analysis. (D) LMP-1 status in dually infected
PELs. Cell lysates from three PEL lines were used for immunoprecipitation/Western blot analyses. BC1, JSC1, and HBL6 are all EBV⫹
KSHV⫹ PEL lines. The specific antibodies for IP and Western blotting
(WB) are indicated. Identities of proteins are as shown.

ISRE probe. The purification process was done according to
the method of our previous report, and partially purified KRTA has the expected properties (91). The same amounts of
partially purified proteins were used for EMSA. The binding of
K-RTA but not K-RTA K152E to the LMP1 ISRE probe was
observed (Fig. 4D). Some bands regularly appeared with our
purified K-RTAs. Purified bovine serum albumin was used to
detect these nonspecific binding patterns. In addition, cold
LMP-ISRE was able to compete for binding to K-RTA, and
the K-RTA-DNA complex could be supershifted by the use of
K-RTA-specific antibody (see Fig. S3C in the supplemental
material). The purified proteins have similar purities as determined by Coomassie blue staining (see Fig. S3D in the supplemental material). These data suggested that K-RTA was
able to bind to LMP-1 ISRE specifically in vitro as expected.
LMP-1 negatively regulates the lytic replication of KSHV.
EBV LMP-1 has been shown to suppress EBV reactivation
triggered by either anti-immunoglobulin M or TPA (3, 63). In
addition, we have shown that LMP-1 is an antiviral protein (87,
90). These published results suggest that LMP-1 might inhibit
the lytic replication of KSHV.
BC-3 cells (KSHV⫹ EBV⫺) were transfected with LMP-1 or
LMP-DM, a LMP-1 mutant that fails to induce an antiviral
state and to inhibit the lytic replication of EBV (63, 90). The
transfected cells were enriched and recovered for several hours
before the addition of TPA (see Materials and Methods for
details). As shown in Fig. 5A, LMP-1 significantly reduced the
expression of K-RTA and K8. Expression of another KSHV
lytic gene, vIRF1, was also inhibited (data not shown). Fur-
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FIG. 7. LMP-1 and K-RTA are expressed during primary infections. (A) KSHV infection induces LMP-1 in EBV latency cells. The KSHV
viruses (0.5 or 1 ml) were used to infect 293-EBV cells for 24 h. Cell lysates were used for Western blot analyses. Identities of proteins are as shown.
(B) K-RTA is involved in induction of LMP-1. 293-EBV cells were first transfected with vector, siRNA for K-RTA (siKRTA), or si-p53 expression
plasmid. The same amounts of KSHV from the same batch were then used to infect these cells a day later. Cell lysates were used for Western blot
analyses. RNA isolated from these cells was used for semiquantitative PCR analyses with primers specific to actin and K-RTA. Identities of
proteins and RNAs are as shown. (C) KSHV infection induces EBV lytic replication. KSHV was used to infect 293-EBV or BZLF1-KO cells. Cell
lysates were used for Western blot analyses. The same membrane was stripped and reprobed with other antibodies. Identities of proteins are as
shown. (D) EBV infection of KSHV induces expression of K-RTA. Cro6 cells were infected by EBV. RNA was isolated 24 h later. RT-PCR was
used for detection of K-RTA, LMP-1, and actin. Identities of products are as shown.

thermore, LMP-DM, which fails to initiate signals from LMP-1
(94), failed to inhibit KSHV lytic replication, suggesting that
the signals derived from LMP-1 are involved in the inhibition.
The recombinant adenovirus containing LMP-1 was also used
to infect BC3 cells. As shown in Fig. 5B, while the infection by
AdGFP still allowed significant lytic replication, the infection
of AdLMP-1 inhibited the expression of K-RTA as well as K8.
Thus, overexpression of EBV LMP-1 inhibits KSHV lytic replication.
Suppression of LMP-1 enhances KSHV lytic replication.
Having established that overexpression of LMP-1 inhibits
KSHV lytic replication, we then examined if endogenous
LMP-1 was involved in the lytic replication of KSHV in dually
infected PEL cell lines. A small interfering RNA for LMP-1
(siLMP-1) expression plasmid was generated and was able to
suppress the expression of LMP-1 significantly in transienttransfection assays with 293T cells (Fig. 6A). siLMP-1 was used
to generate a stable cell line with BC1 cells, a PEL line dually
infected with both EBV and KSHV, and was able to suppress
endogenous LMP-1 expression (Fig. 6B). Sodium butyrate was
able to selectively induce the lytic replication of KSHV but not
EBV (74). Upon the induction of KSHV lytic replication by
sodium butyrate, the siLMP-1-expressing cells had higher expression of K-RTA and K8 than control cells (Fig. 6C). The
LMP-1 protein was detectable in several dually infected PEL
lines by immunoprecipitation (IP)-Western blot analysis (Fig.

6D). The majority of LMP-1 proteins were lost during the
immunoprecipitation process under our experimental condition; the use of IP to show the quantitative differences was
unreliable. In addition, immunostaining of LMP-1 and K-RTA
in dually infected BC1 cells after treatment with sodium butyrate showed that the majority of cells were either K-RTA or
LMP-1 positive, and only a small fraction (⬍10%) were positive for both (data not shown). All of these data suggested that
endogenous LMP-1 was contributing to the control of KSHV
lytic replication in dually infected PELs.
Expression of LMP-1 during primary infections. To address
if the interaction between K-RTA and LMP-1 is relevant to the
establishment of latencies in dually infected PELs, we examined if LMP-1 is induced during primary infections. First,
whether LMP-1 is inducible during KSHV infection of EBV
latency cells was examined. 293-EBV cells (KSHV⫺ EBV⫹)
were used for the infection by concentrated KSHV. The reason
for choosing 293-EBV is that KSHV apparently infects fibroblasts efficiently (49). Given the fact that infection by KSHV of
B cells is inefficient (19, 44), infection of 293-EBV cells may be
the best available alternative to address alterations in EBV
gene expression during primary infection of KSHV. As shown
in Fig. 7A, LMP-1 is highly induced by KSHV infection. KRTA is expressed during primary infection (49). Whether KRTA is involved in the induction of EBV LMP-1 in primary
infection was addressed by the use of siRNA for K-RTA. After
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the transfection of siRNA for K-RTA into 293-EBV cells, the
expression of both LMP-1 and K-RTA was reduced upon
KSHV infection, suggesting the involvement of K-RTA in the
induction (Fig. 7B).
Second, we examined if LMP-1 is expressed during EBV
infection of KSHV latency cells. EBV was used to infect Cro6
(KSHV⫹ EBV⫺) cells. RNA was isolated from infected cells
for RT-PCR analyses 24 h later. The infection of KSHV latency cells by EBV was associated with EBV LMP-1 expression
(Fig. 7D). Therefore, in both scenarios, LMP-1 is expressed
during primary infections.
Induction of lytic replications during primary infection.
EBV latency can be disrupted by several treatments, including
viral superinfection (4, 21, 29). To test what may happen in
EBV latency, we examined if KSHV could disrupt EBV latency
by inducing lytic replication of EBV. EBV EA-D (BMRF-1)
expression was used as a marker for lytic replication. The
essential function of EA-D in EBV lytic replication has been
well established, and use of EA-D as an indicator of lytic
replication has been appreciated in the field for years (28, 32,
34, 78–80, 89, 90). KSHV infection of 293-EBV induced EBV
EA-D expression (Fig. 7C). Thus, KSHV infection of EBV
latency cells induced EBV lytic replication. However, KSHV
infection still induced LMP-1 in BZLF1-KO (KSHV⫺ EBV⫹)
cells, in which EBV lytic replication could not be induced (27)
(Fig. 7C), suggesting that EBV lytic replication plays a limited
role in the induction of LMP-1 by KSHV.
Finally, EBV was used to infect KSHV⫹ EBV⫺ PEL cells.
Because infection by EBV of Cro6 cells is inefficient (⬍5%;
data not shown), RT-PCR was used to detect the expression of
K-RTA expression. As shown in Fig. 7D, infection of Cro6
(KSHV⫹ EBV⫺) cells by EBV induced K-RTA expression.
Due to well-established functions of K-RTA, the results also
suggested that EBV infection might induce lytic replication of
KSHV.

dually infected PEL cells enhanced the lytic replication process
(Fig. 6). Therefore, a regulatory loop between two human
herpesviruses (KSHV and EBV) is identified, i.e., K-RTA induces LMP-1, and LMP-1 in turn down-regulates K-RTA.
Based on the fact that dually infected cells do express LMP-1
(Fig. 7D), it is likely that endogenous LMP-1 plays a role in the
control of KSHV lytic replication and the regulatory loop between K-RTA and LMP-1 may be responsible for the observed
inhibitory effects of EBV on KSHV lytic replication (Fig. 1). In
addition, LMP-1 is known to inhibit EBV lytic replication (3,
63). Thus, KSHV would potentiate EBV latency by inducing
LMP-1. Due to the well-established functions of LMP-1 in
cellular transformation and invasive potential, the regulatory
loop between K-RTA and LMP-1 may also contribute to the
pathogenesis of AIDS-associated PELs.
Because K-RTA is necessary and sufficient for KSHV lytic
replication, LMP-1-mediated inhibition of KSHV lytic replication is at least partially via the inhibition of K-RTA expression.
EBV LMP-1 has at least two mechanisms for the inhibition of
EBV lytic replication, and one of them is to downregulate the
expression of essential genes for EBV lytic replication, such as
the E-RTA gene (3). NF-B has been shown to be a negative
regulator of gammaherpesvirus lytic replication (10). LMP-1 but
not LMP-DM induces NF-B activity (94). Because LMP-DM
failed to inhibit KSHV lytic replication, LMP-1-mediated NF-B
activation is apparently associated with the inhibition of KSHV
lytic replication. Thus, the finding that LMP-1 inhibits the lytic
replication process of KSHV might be in agreement with previously identified mechanisms for LMP-1 control of EBV lytic
replication.
How both viruses establish their latencies in PEL cells is
unknown. It is known that viral infection is a common inducer
of EBV lytic replication (90). As expected, KSHV infection of
EBV latency cells induces EBV lytic replication (Fig. 7C). In
addition, EBV infection of KSHV latency cells might trigger
KSHV lytic replication by induction of K-RTA (Fig. 7D). It is
very interesting to address how the two viruses could establish
latencies in the same cells. LMP-1 is expressed during either
KSHV infection of EBV latency cells or EBV infection of
KSHV latency cells (Fig. 7). Therefore, the antiviral and repression-of-reactivation properties of LMP-1 plus its temporal
expression during primary infection may inhibit both EBV and
KSHV lytic replications and promote establishment of latency
for both viruses during primary infections. Of note is that the
LMP-1 protein may be present in EBV virions and is possibly
delivered into cells directly during the infection (24, 57), which
could have a profound effect on the outcome of infection.
In summary, this report shows that two human oncogenic
herpesviruses interact at the molecular level to reinforce each
other’s latency in the same tumor cells, and the regulatory loop
of K-RTA and LMP-1 may contribute to dual latency and the
pathogenesis of PELs.

DISCUSSION
By using isogenic cell lines, we discovered that EBV inhibited the lytic replication of KSHV (Fig. 1). Support for this
conclusion also comes from the finding that TPA induces
KSHV lytic replication in KSHV singly infected PELs but not
in dually infected PELs (58) and an apparent negative correlation between spontaneous KSHV lytic gene expression and
EBV infection in primary PEL specimens (25). It is also possible that KSHV inhibits EBV reactivation, because sodium
butyrate and/or TPA induces EBV lytic replication in EBV
singly infected cells, but in dually infected BC1 cells, only TPA
induces EBV lytic replication (58). Because we were unable to
generate dually infected lines in EBV latency cells, the direct
effect of KSHV on EBV lytic replication could not be tested
(data not shown).
To address the potential mechanism of EBV-mediated inhibition of KSHV lytic replication, we found that K-RTA in
EBV latency cells induces LMP-1 in an EBNA-2-independent
manner at the RNA level (Fig. 2 and 3). K-RTA activates
LMP-1 promoter reporter constructs and binds to the LMP-1
promoter region (Fig. 4). Overexpression of LMP-1 in PEL cell
lines inhibited chemical-mediated induction of lytic replication
processes (Fig. 5). The suppression of LMP-1 expression in
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SUPPLEMENTARY FIGURE LEGENDS
Supplementary Figure 1: Expression of EBV LMP-1 in dually infected PELs. The total RNAs
from indicated cell lines were isolated, digested with DNase, and reverse transcribed. RT-PCR was
used to detect the expression of LMP-1. The identity of RNAs is as shown.
Supplementary Figure 2: Detection of KSHV and EBV in PELs. (A) Detection of KSHV LANA
expression in PELs. Growing PEL cells were washed, fixed, and permeabilized. The cells were then
stained with LANA antibody and secondary antibody conjugated with Cy5, and counterstained with
propidium iodide (PI). Cells were visualized by a confocal microscope. (B) Detection the percentage
of GFP-positive cells. Growing PEL cells were washed twice with 1x PBS, and subjected to
fluorescence-activated cell sorting (FACS) analysis. Live cells were gated and assayed for GFP
intensity. The GFP profiles of the cells were plotted, and the percentage of GFP-positive cells was
calculated. Solid lines: BC3 or Cro6 cells; dashed lines: BC3-EBV or Cro6-EBV.
Supplementary Figure 3: (A) Expression of RTA and its mutant in transfected cells. Lysates
from pcDNA3, RTA, or RTA-K152E transfected 293T cells were used for western blot analysis with
K-RTA and tubulin antibodies. Same membrane was used for both antibodies. The identity of proteins
is as shown. (B) Expression of RTA in BC3 cells. Lysates from sodium butyrate treated BC3 cells
were used for western blot analysis with K-RTA and tubulin antibodies. The identity of proteins is as
shown. (C) K-RTA binds to LMP1 ISRE. The LMP1 ISRE probe was labeled with [α-32P]-dCTP.
Cold probe, LMP-ISRE, was added at 50-fold molar excess over hot probe. Purified bovine serum
albumin (BSA) was used as negative controls. Normal rabbit serum (NRS), Rabbit polyclonal AntiRTA or IRF-1 were used for super shift analyses. Specific protein-DNA complexes are as shown. ss:
super-shifted complex. (D) The purity of purified K-RTAs. Coomassie blue staining of the partially
purified E. coli-derived K-RTA and its mutant K-RTA K152E proteins. The identities of these
proteins were confirmed by western blot (data not shown).
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